“Flynn Management LLC, General Partner”

As a Name:  Registrant, Group Member and/or Signatory

        

Latest Filing:  5/15/24  as  ↓Signatory

        

As:  Signatory  (Director, Officer, Attorney, Accountant, Banker, Agent, etc.)

“Flynn Management LLC, General Partner” has been a Signatory for/with  26  Filers:

        

As Of	Filer			Filings       #        Latest		Issuer     (Primary)
5/15/24		NY	Flynn James E	605	SC 13G/A	MA	Nuvalent, Inc.
3/19/24		NY	Deerfield Healthcare Innovations Fund II, L.P.	2	4		BiomX Inc.
3/19/24		NY	Deerfield Management Co., L.P. (Series C)	393	4		BiomX Inc.
3/19/24		NY	Deerfield Mgmt HIF, L.P.	31	4		BiomX Inc.
3/19/24		NY	Deerfield Mgmt V, L.P.	6	4		BiomX Inc.
3/19/24		NY	Deerfield Private Design Fund V, L.P.	4	4		BiomX Inc.
3/19/24		NY	Deerfield Mgmt HIF II, L.P.	1	3		BiomX Inc.
3/12/24		NY	Deerfield Mgmt IV, L.P.	41	4	PA	AdaptHealth Corp.
3/12/24		NY	Deerfield Mgmt L.P.	339	4	PA	AdaptHealth Corp.
3/12/24		NY	Deerfield Partners, L.P.	169	4	PA	AdaptHealth Corp.
3/12/24		NY	Deerfield Private Design Fund IV, L.P.	41	4	PA	AdaptHealth Corp.
2/16/24		NY	Deerfield Healthcare Innovations Fund, L.P.	30	4	PA	Larimar Therapeutics, Inc.
2/16/24		NY	Deerfield Mgmt III, L.P.	76	4	PA	Larimar Therapeutics, Inc.
2/16/24		NY	Deerfield Private Design Fund III, L.P.	76	4	PA	Larimar Therapeutics, Inc.
7/13/21		NY	Deerfield Special Situations Fund, L.P.	255	4	CA	Mirum Pharmaceuticals, Inc.
8/7/20		CA	Endologix Inc./DE	1	10-Q	—
6/25/18		NY	Breaking Stick Holdings, LLC	2	4		Avadel Pharmaceuticals plc
6/25/18		NY	Deerfield Private Design Fund II, L.P.	26	4		Avadel Pharmaceuticals plc
6/25/18			Deerfield Private Design International II, L.P.	21	4		Avadel Pharmaceuticals plc
12/4/17		NY	Deerfield International Master Fund, L.P.	54	4	NY	Protara Therapeutics, Inc.
			More...  Please Sign In to list all 26 of them.

“Flynn Management LLC, General Partner” has/had a Signatory interest in  155  Issuers:

As Of	Issuer			Filings       #        Latest		With Filer     (Primary)
5/15/24		MA	Nuvalent, Inc.	11	SC 13G/A	NY	Flynn James E
4/24/24		MA	Cullinan Therapeutics, Inc.	1	SC 13G	NY	Flynn James E
4/4/24		CA	Ventyx Biosciences, Inc.	1	SC 13G	NY	Flynn James E
3/22/24			BiomX Inc.	3	SC 13D	NY	Flynn James E
3/12/24		PA	AdaptHealth Corp.	10	4	NY	Deerfield Management Co., L.P. (Series C)
2/16/24		PA	Larimar Therapeutics, Inc.	12	4	NY	Deerfield Management Co., L.P. (Series C)
2/12/24		TX	Nuo Therapeutics, Inc.	2	SC 13G/A	NY	Flynn James E
2/12/24		CA	Kura Oncology, Inc.	4	SC 13G/A	NY	Flynn James E
2/12/24			Merus N.V.	3	SC 13G/A	NY	Flynn James E
2/12/24		MA	Deciphera Pharmaceuticals, Inc.	5	SC 13G/A	NY	Flynn James E
2/12/24		FL	Catalyst Pharmaceuticals, Inc.	3	SC 13G/A	NY	Flynn James E
2/12/24		MA	Vigil Neuroscience, Inc.	3	SC 13G/A	NY	Flynn James E
2/12/24		CA	Singular Genomics Systems, Inc.	6	SC 13G/A	NY	Flynn James E
2/12/24		CA	Pulmonx Corp.	5	SC 13G/A	NY	Flynn James E
2/12/24		DE	Prelude Therapeutics Inc.	2	SC 13G/A	NY	Flynn James E
2/12/24		VA	Owens & Minor Inc./VA	2	SC 13G/A	NY	Flynn James E
2/12/24		NY	Oscar Health, Inc.	2	SC 13G/A	NY	Flynn James E
2/12/24			Mallinckrodt plc	4	SC 13G/A	NY	Flynn James E
2/12/24		MA	HilleVax, Inc.	3	SC 13G/A	NY	Flynn James E
2/12/24		TX	Enhabit, Inc.	3	SC 13G/A	NY	Flynn James E
			More...  Please Sign In to list all 155 of them.